We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AI Could Help Identify Early Skin Cancer

By LabMedica International staff writers
Posted on 05 Sep 2017
Print article
Image: New AI technology may help detect melanoma skin cancer earlier than current methods and to help reduce the number of unnecessary biopsies (Photo courtesy of Deposit Photos).
Image: New AI technology may help detect melanoma skin cancer earlier than current methods and to help reduce the number of unnecessary biopsies (Photo courtesy of Deposit Photos).
Newly developed technology uses artificial intelligence (AI) to help detect melanoma skin cancer earlier than current methods and to help reduce the number of unnecessary biopsies. The AI-based method employs machine-learning software to analyze images of skin lesions and to provide doctors with objective data on telltale biomarkers of melanoma.

"This could be a very powerful tool for skin cancer clinical decision support," said Alexander Wong, professor at University of Waterloo (Waterloo, ON, Canada), "The more interpretable information there is, the better the decisions are." Prof. Wong developed the technology in collaboration with Daniel Cho, former PhD student at Waterloo, David Clausi, professor at Waterloo, and Farzad Khalvati, adjunct professor at Waterloo and scientist at Sunnybrook.

Currently, dermatologists largely rely on subjective visual examinations of skin lesions (e.g. moles) to decide if patients should undergo biopsies to diagnose the disease. The new system deciphers levels of biomarker substances in lesions, adding consistent, quantitative information to assessments currently based on visual appearance alone. In particular, changes in the concentration and distribution of eumelanin (gives color to skin) and hemoglobin are strong indicators of melanoma.

"There can be a huge lag-time before doctors even figure out what is going on with the patient," said Prof. Wong, "Our goal is to shorten that process." The AI system was trained using tens of thousands of skin images and their corresponding eumelanin and hemoglobin levels. It gives doctors objective information on lesion characteristics to help them identify or rule out melanoma before deciding if to take more invasive action. The technology could be available to doctors as early as 2018.

The research was recently presented at the 14th International Conference on Image Analysis and Recognition (ICIAR 2017, July 5-7, 2017, Montreal, Canada).

Related Links:
University of Waterloo

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more